Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-139598

Published: 2020

Journal Articles

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Denis Claude Roy, MD, Irwin Walker, MBBS, FRCPC, Johan A. Maertens, MD PhD, Philippe Lewalle, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva Maria Wagner, MD, Halvard Bönig, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2019) 134 (Supplement_1): 592.

https://doi.org/10.1182/blood-2019-128344

Published: 2019

Journal Articles

Head-to-Head Comparison of Haploidentical HSCT Strategies for Hematologic Malignancies: Phase III Hatcy Study of T-Cell-Depleted HSCT with Adjunctive ATIR101 Versus T-Cell-Replete HSCT with Post‐Transplant Cyclophosphamide

Denis Claude Roy, MD, Bernd-Jan Sanson, Jonas Hylton, PharmD, Andrew Sandler, MD, Stephan Mielke, MD

Blood (2019) 134 (Supplement_1): 4464.

https://doi.org/10.1182/blood-2019-125592

Published: 2019

Journal Articles

UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies

Sandra Cohen, MD FRCP(C), Jean Roy, MD, Jean-Sébastien Delisle, MD PhD, Nadia M. Bambace, MD, Imran Ahmad, MD, Silvy Lachance, MD FRCP, Léa Bernard, MD, Frederic Barabe, MD, Thomas L. Kiss, MD, Lambert Busque, MD, Denis-Claude Roy, MD, Filippo Milano, MD PhD, Guy Sauvageau, MD PhD

Blood (2019) 134 (Supplement_1): 3245.

https://doi.org/10.1182/blood-2019-121698

Published: 2019

Journal Articles

Depletion of Alloreactive T Cells after Haploidentical HSCT: Comparison of Outcomes for Ex Vivo Versus In Vivo Treatment Strategies

Steven Devine, Stephan Mielke, MD, Eduardo Olavarria, Bert Tuk, Kees Meewisse, Andrew Sandler, MD, Denis-Claude Roy, MD

Blood (2018) 132 (Supplement 1): 3474.

https://doi.org/10.1182/blood-2018-99-118857

Published: 2018

Journal Articles

Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies

Denis-Claude Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD, Philippe Lewalle, MD, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva-Maria Wagner, MD, Halvard Bonig, MD, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2018) 132 (Supplement 1): 120.

https://doi.org/10.1182/blood-2018-99-119086

Published: 2018

Journal Articles

Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival

Blood (2018) 132 (Supplement 1): 4658.

https://doi.org/10.1182/blood-2018-99-110188

Published: 2018

Journal Articles

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Richard Leblanc, MD FRCPC, Imran Ahmad, MD MPH, Rafik Terra, PhD, Séverine Landais, PhD, Céline Nkoue, MD, Michael Sebag, MD PhD, Émilie Lemieux Blanchard, MD FRCPC, Nadia M. Bambace, MD, Léa Bernard, MD, Sandra Cohen, MD FRCP(C), Jean-Sébastien Delisle, MD PhD, Thomas L. Kiss, MD, Silvy Lachance, MD FRCP, Denis-Claude Roy, MD, Guy Sauvageau, MD, PhD, Jean Roy, MD

Blood (2018) 132 (Supplement 1): 4666.

https://doi.org/10.1182/blood-2018-99-112313

Published: 2018

Journal Articles

Prediction of Severe Acute Graft-Versus-Host Disease (aGVHD) Based on Whole Transcriptome Sequencing of Donor CD4 T Cells

Silvy Lachance, MDFRCPC, Jonathan Séguin, MSc., Ann Brasey, PhD, Jean-Philippe Laverdure, PhD, Vincent T Ho, MD, Jerome Ritz, MD, Jan Storek, MD PhD, Denis-Claude Roy, MD, Lambert Busque, MD, Sébastien Lemieux, PhD, Claude Perreault, MD

Blood (2017) 130 (Supplement 1): 3249.

https://doi.org/10.1182/blood.V130.Suppl_1.3249.3249

Published: 2017

Journal Articles

Impact of Carmustine (BCNU) Substitution for Bendamustine in the Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation for the Treatment of Lymphoma

Josie-Anne Boisjoly, MD, Philippe Bouchard, BPharm, Sandra Cohen, MD FRCP(C), Imran Ahmad, MD, Nadia M. Bambace, MD, Léa Bernard, MD, Jean-Sébastien Delisle, MD PhD, Thomas L Kiss, MD, Denis-Claude Roy, MD, Guy Sauvageau, MD, PhD, Jean Roy, MD, Silvy Lachance, MDFRCPC

Blood (2017) 130 (Supplement 1): 2022.

https://doi.org/10.1182/blood.V130.Suppl_1.2022.2022

Published: 2017

Journal Articles

Single UM171 Expanded Cord Blood Transplant Is Feasible, Safe, and Permits Transplantation of Better HLA Matched Cords with Very Low Transplant Related Mortality

Sandra Cohen, MD, Jean Roy, MD, Silvy Lachance, MDFRCPC, Anne Marinier, PhD, Denis-Claude Roy, MD, Jean-Sébastien Delisle, MD PhD, Lambert Busque, MD, Pierre Caudrelier, MD, Fannie Larochelle, Philippe Bouchard, BPharm, Jean Roy, MD, Nadia M. Bambace, MD, Léa Bernard, MD, Thomas L Kiss, MD, Sébastien Lemieux, PhD, Peter W. Zandstra, PhD, Guy Sauvageau, MD, PhD

Blood (2017) 130 (Supplement 1): 658.

https://doi.org/10.1182/blood.V130.Suppl_1.658.658

Published: 2017

Journal Articles

The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity

Blood (2017) 130 (Supplement 1): 45.

https://doi.org/10.1182/blood.V130.Suppl_1.45.45

Published: 2017

Journal Articles

Bortezomib Consolidation after Nonmyeloablative Allogeneic Transplant Is Safe and Leads to a High Incidence of Immunophenotypic Complete Response in High-Risk or Young Myeloma Patients

Richard LeBlanc, MDFRCPC, Imran Ahmad, MD M.Sc., Rafik Terra, PhD, Séverine Landais, PhD, Michael Sebag, MD PhD, Emilie Lemieux-Blanchard, MD, Nadia M. Bambace, MD, Léa Bernard, MD, Sandra Cohen, MD, Jean-Sébastien Delisle, MD PhD, Thomas Kiss, MD, Silvy Lachance, MDFRCPC, Denis-Claude Roy, MD, Guy Sauvageau, MD PhD, Jean Roy, MD

Blood (2017) 130 (Supplement 1): 4556.

https://doi.org/10.1182/blood.V130.Suppl_1.4556.4556

Published: 2017

Journal Articles

Potential Targeting Ph + Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity

Justine Yu, B.S., Giovannino Silvestri, PhD, Lorenzo Stramucci, PhD, Masashi Sanada, MD PhD, Tomoyuki Yamaguchi, PhD, Yang Du, PhD, Jukka Westermarck, MD PhD, Michael A. Caligiuri, MD, Ramiro Garzon, MD, Dragana Milojkovic, MD, Jane F. Apperley, MD, Denis-Claude Roy, MD, Guido Marcucci, MD, Bruno Calabretta, MD PhD, Maria R. Baer, MD, Rossana Trotta, PhD, Danilo Perrotti, MD PhD

Blood (2016) 128 (22): 2909.

https://doi.org/10.1182/blood.V128.22.2909.2909

Published: 2016

Journal Articles

Tandem Autologous Followed By Nonmyeloablative Allogeneic Transplantation in Relapsed High Risk Follicular Lymphoma Leads to Excellent Long Term Progression-Free Survival after 8 Years of Follow-up

Magalie Tardif, MSc, MD Student, Imran Ahmad, MD, Nadia M. Bambace, MD, Lea Bernard, MD, Lambert Busque, MD PhD FRCPC, Jean-Sebastien Delisle, MD PhD, Thomas Kiss, MD, Isabelle Fleury, MD, Silvy Lachance, MD, Luigina Mollica, MD PhD, Céline Nkoué, MD, Denis-Claude Roy, MD, Jean Roy, MD, Sandra Cohen, MD

Blood (2016) 128 (22): 4677.

https://doi.org/10.1182/blood.V128.22.4677.4677

Published: 2016

Journal Articles

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL

Denis-Claude Roy, MD, Silvy Lachance, MD, Jean Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD PhD, Jean-Sebastien Delisle, MD PhD, Stephen Ronan Foley, MD, Philippe Lewalle, MDPhD, Eduardo Olavarria, Dominik Selleslag, MD, Manfred Rüdiger, PhD, Jurjen Velthuis, PhD, Lisya Gerez, Jeroen Rovers, MD PhD, Halvard Bonig, MD MA, Stephan Mielke, MD

Blood (2016) 128 (22): 1226.

https://doi.org/10.1182/blood.V128.22.1226.1226

Published: 2016

Journal Articles

Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients

Richard LeBlanc, MD, Imran Ahmad, MD, Rafik Terra, PhD, Séverine Landais, PhD, Michael Sebag, MD PhD, Emilie Lemieux-Blanchard, MD, Nadia M. Bambace, MD, Lea Bernard, MD, Sandra Cohen, MD, Jean-Sebastien Delisle, MD PhD, Thomas Kiss, MD, Silvy Lachance, MD, Denis-Claude Roy, MD, Guy Sauvageau, MD PhD, Jean Roy, MD

Blood (2016) 128 (22): 2306.

https://doi.org/10.1182/blood.V128.22.2306.2306

Published: 2016

Journal Articles

Phase I Study of Non-Engrafting Allogeneic, Mismatched, Unmanipulated Peripheral Blood Mononuclear Cell Infusions to Treat Poor-Prognosis Acute Myeloid Leukemia

Elizabeth F Krakow, MD MSc, Julie Bergeron, MD, Silvy Lachance, MD, Denis-Claude Roy, MD, Jean-Sebastien Delisle, MD PhD

Blood (2015) 126 (23): 2562.

https://doi.org/10.1182/blood.V126.23.2562.2562

Published: 2015

Journal Articles

Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML

Blood (2015) 126 (23): 53.

https://doi.org/10.1182/blood.V126.23.53.53

Published: 2015

Journal Articles

Disruption of the Peripheral Lymphoid Niche Contributes to Lymphopenia in CML Patients Undergoing Imatinib Treatments

Stephanie Thiant, PhD, Moutuaata M.Moutuou, Philippe Laflamme, Radia Sidi Boumedine, Fanny Larochelle, Dominique Leboeuf, Denis-Claude Roy, MD, Martin Guimond, PhD

Blood (2015) 126 (23): 5165.

https://doi.org/10.1182/blood.V126.23.5165.5165

Published: 2015

NARROW

UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Head-to-Head Comparison of Haploidentical HSCT Strategies for Hematologic Malignancies: Phase III Hatcy Study of T-Cell-Depleted HSCT with Adjunctive ATIR101 Versus T-Cell-Replete HSCT with Post‐Transplant Cyclophosphamide

UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies

Depletion of Alloreactive T Cells after Haploidentical HSCT: Comparison of Outcomes for Ex Vivo Versus In Vivo Treatment Strategies

Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies

Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Prediction of Severe Acute Graft-Versus-Host Disease (aGVHD) Based on Whole Transcriptome Sequencing of Donor CD4 T Cells

Impact of Carmustine (BCNU) Substitution for Bendamustine in the Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation for the Treatment of Lymphoma

Single UM171 Expanded Cord Blood Transplant Is Feasible, Safe, and Permits Transplantation of Better HLA Matched Cords with Very Low Transplant Related Mortality

The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity

Bortezomib Consolidation after Nonmyeloablative Allogeneic Transplant Is Safe and Leads to a High Incidence of Immunophenotypic Complete Response in High-Risk or Young Myeloma Patients

Potential Targeting Ph + Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity

Tandem Autologous Followed By Nonmyeloablative Allogeneic Transplantation in Relapsed High Risk Follicular Lymphoma Leads to Excellent Long Term Progression-Free Survival after 8 Years of Follow-up

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL

Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients

Phase I Study of Non-Engrafting Allogeneic, Mismatched, Unmanipulated Peripheral Blood Mononuclear Cell Infusions to Treat Poor-Prognosis Acute Myeloid Leukemia

Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML

Disruption of the Peripheral Lymphoid Niche Contributes to Lymphopenia in CML Patients Undergoing Imatinib Treatments

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only